In silico analysis identifying overlapped genes between diabetes and breast cancer, targeting candidates via doxazosin mesylate, a comprehensive analysis

Abstract

Breast cancer and diabetes share common molecular interactions, mainly through the activation of the breast cancer signaling pathway, namely PI3K/AKT/mTOR and insulin signaling. These common signaling associations can reveal a dysfunction in the metabolic order that can influence breast cancer growth and lead to becoming more aggressive and metastasis. In this in silico research, the potential of Doxazosin Mesylate to target crosstalk signaling diseases, namely breast cancer and diabetes. Doxazosin mesylate has a significant in-vitro analysis by exhibiting the cell viability of breast cancer cell line, a comprehensive in-silico analysis is performed to support the importance of targeting diabetes-related proteins using GNINA AI-based molecular docking tool. This study aims to identify whether the insulin signaling candidates need to be emphasized in the therapeutic target approach of breast cancer or not. The bioinformatic analysis revealed a strong binding affinity of IRS2 with Doxazosin Mesylate, suggesting a potential therapeutic target that can enhance the treatment outcomes by interfering with treatment resistance and responses. The studies’ findings illustrated that, meanwhile, Doxazosin Mesylate acts primarily on the oncogenes; they have other interactions with the insulin protein pathway. This supports that it should be taken as a biological consideration and a secondary target candidate for breast cancer.